Monday, 24 March 2014

BrainStorm receives US Patent for its autologous stem cell technology

BrainStorm Cell Therapeutics logo
BrainStorm Cell Therapeutics announced this Monday that the U.S. Patent and Trademark Office has granted the company a key patent for its autologous stem cell technology.

The patent covers BrainStorm's stem cells induced to secrete elevated levels of neurotrophic factors for the treatment of neurodegenerative diseases.

Pending approval from the U.S. FDA, Brainstorm is preparing for its upcoming mid-stage Phase II trial in the United States with its NurOwn adult stem cell therapy.


BrainStorm is developing NurOwn for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease, a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord.

The company also mentioned that it has signed a definitive agreement with Massachusetts General Hospital in Boston to conduct a Phase II clinical trial of NurOwn in ALS, pending FDA approval. The other two clinical sites slated for the trial are the University of Massachusetts Memorial Hospital and Mayo Clinic.

"The recent bill introduced to the U.S. Senate to support regenerative medicine research is yet another indication of the increasing recognition that stem cells hold the promise for curing life-threatening and debilitating conditions like ALS. We are very encouraged by the bill's proposal to appoint a council that would develop and maintain a national strategy for the promotion of regenerative medicine research and development." said Chaim Lebovits, BrainStorm's president.

References

No comments:

Post a Comment

Please note that we dont offer any kind of medical advice. Questions requesting specific medical advice (e.g. where can I get this treatment, will this cure XXX condition, etc) will be published but most probably ignored by the administrators. :)

Note to spammers: You shall not pass. If you really want a link from us then consider making a stem cell related guest post !